ImmunoTargets and Therapy (Oct 2020)
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
Abstract
Omar Nadeem, Yu-Tzu Tai, Kenneth C Anderson Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USACorrespondence: Omar NadeemDana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USATel +1 617-632-3000Email [email protected]: The multiple myeloma (MM) therapeutic landscape has evolved significantly with the approval of numerous novel agents, including next generation proteasome inhibitors (PIs), immunomodulatory agents (IMIDs), and monoclonal antibodies (MoABs) targeting CD38 and SLAMF7. While these discoveries have led to an unprecedented improval in patient outcomes, the disease still remains incurable. Immunotherapeutic approaches have shown substantial promise in recent studies of chimeric antigen receptor T-cell (CAR T-cell) therapy, bispecific antibodies, and antibody drug conjugates targeting B-cell maturation antigen (BCMA). This review will highlight these novel and targeted therapies in MM, with particular focus on PIs, IMIDs, MoAb and BCMA-directed immunotherapy.Keywords: immunotherapy multiple myeloma, chimeric antigen receptor T-cell therapy; CAR T-cell therapy, bispecific antibodies, immunomodulatory agents; IMID, monoclonal antibodies; MoAB
